CytoDyn Inc. CYDY
0.25 USD 0.00 (-0.28%)
As ofNov 17, 2026, 3:52 PM EST
0.2421 Day range 0.2592
0.18 52-week range 0.40
- YTD
- -10.89%
- 1 year
- -19.52%
News
globenewswire.com CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs VANCOUVER, Washington, Nov. 17, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
globenewswire.com CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors VANCOUVER, Washington, Nov. 12, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
globenewswire.com CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer VANCOUVER, Washington, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
